Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - August 2025

Despite the ongoing turmoil over tariffs, medicine costs, and FDA policy, US wholesalers are performing well.

Pharma Wholesalers: Looking for Growth

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can safeguard profitability in a volatile market.

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.

340B Litigation and the Path Toward Transparent Drug Discount Programs

Articles

The CDMO’s new services at its Hopewell, NJ facility delivers scalable, phase-appropriate production, in-house quality control, and domestic sourcing to help gene therapy developers reduce complexity, speed timelines, and ensure regulatory compliance.

ProBio Debuts End-to-End GMP AAV Manufacturing to Accelerate Gene Therapy Development

The GSK Flovent example highlights the consequences for patients and pharma of the decision to eliminate the Medicaid rebate cap.

A Rebate Double-Whammy: Exploring the Unintended Consequences 

. He can be reached at nsaraceno@mjhlifesciences.com.

Podcasts

This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 million mRNA patent settlement with CureVac, and upcoming discussions between industry leaders and policymakers on strengthening US pharmaceutical innovation and supply chains.

Pharma Pulse: FDA Launches Pre-Check Program, GSK Secures mRNA Settlement, and Pharma Leaders Eye US Investment Boost

Videos

In the seventh part of this roundtable discussion, key opinion leaders uncover how pharma companies can mitigate tariff impact through duty drawback programs and smart technology investments, without overreacting or overhauling manufacturing footprints unnecessarily.

Peer Exchange: Maximizing Supply Chain Efficiency Without Overreacting to Tariffs (Episode 7)

A new two-phase initiative aims to streamline facility approvals, reduce reliance on foreign pharmaceutical production, and bolster domestic supply chain resilience amid rising tariffs and reshoring investments.

FDA Launches PreCheck Program to Strengthen US Drug Manufacturing

In an era of increasing regulatory complexity, life sciences organizations are modernizing GxP compliance through digital tools like eQMS, cloud platforms, and automated validation, while expert validation services remain essential for aligning these technologies with real-world workflows and inspection readiness.

Modernizing GxP Compliance in Life Sciences: The Role of Digital Tools and Validation Expertise

This episode of Pharma Pulse covers Bayer’s $2.3 billion cost-cutting overhaul, promising Phase III results for Eli Lilly’s oral GLP-1 therapy orforglipron, and a pivotal court decision clearing the way for intensified competition in the high-growth obesity and diabetes treatment market.

Pharma Pulse: Bayer Restructures, Lilly’s Oral GLP-1 Advances, and Court Ruling Shakes Up Obesity Drug Market

In the third part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, explains how pharma companies can strategically evaluate AI investments across functions like R&D, pharmacovigilance, and supply chain, ensuring early automation gains and long-term value without intensifying short-term financial strain.

Balancing AI Ambition With Cost Pressures in Pharma

Meanwhile, drugmakers ramp up US manufacturing investments to navigate policy shifts and protect supply chain resilience, as the Trump administration enacted tariff rates between 10% to 50% on various trading partners early this morning.

Trump: Tariffs Could Potentially Hit 250%

This episode of Pharma Pulse examines how in-store pharmacies are evolving beyond prescriptions to deliver clinical services, nutrition support, and real-time education, bridging care gaps in pharmacy deserts across the United States.

Featured Content

Pharmaceutical Commerce - August 2025

Pharma Wholesalers: Looking for Growth

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

340B Litigation and the Path Toward Transparent Drug Discount Programs